Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 7/20 | 0.62 |
| ▸ | RXRB | P28702 | 6/20 | 0.62 |
| ▸ | RXRG | P48443 | 5/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | XDH | P47989 | 2/20 | 0.58 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.57 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.56 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.56 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3648209 | 0.91 | RXRA (0.60) | RXRARXRBRXRGHPGDXDH | |
| SCHEMBL23657704 | 0.87 | PARP1 (0.65) | RXRAXDH | |
| SCHEMBL3642605 | 0.87 | RXRA (0.50) | RXRARXRBRXRGHPGDXDH | |
| SCHEMBL3647437 | 0.85 | RAB9A (0.60) | RXRAHPGDKMT2A | |
| SCHEMBL448079 | 0.84 | MAOB (0.57) | XDH | |
| SCHEMBL5026568 | 0.84 | XDH (0.71) | HPGDXDH | |
| SCHEMBL13881264 | 0.83 | FFAR1 (0.50) | XDHLPAR1LPAR5 | |
| SCHEMBL25216997 | 0.81 | XDH (0.66) | XDHKMT2APTGER1 | |
| SCHEMBL3080346 | 0.78 | — | — | |
| SCHEMBL13881445 | 0.78 | SMN1; SMN2 (0.46) | HPGDXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20100311748-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | disclosed |
| EP-2188255-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | AstraZeneca AB (SE) | 2010-05-26 | — | — | EP | disclosed |
| EP-1317419-B1 | CYANOPHENOXY CARBOXYLIC ACID COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1317419-B1 | CYANOPHENOXY CARBOXYLIC ACID COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009027746-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | WO | disclosed |
| US-7390834-B2 | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390834-B2 | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390834-B2 | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20060264356-A1 | CYANOPHENOXY CARBOXYLIC ACID COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-11-23 | — | — | US | disclosed |
| US-7115663-B2 | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1597228-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| EP-1317419-A4 | CYANOPHENOXY CARBOXYLIC ACID COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| WO-2004072025-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
| US-20030199427-A1 | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2003-10-23 | — | — | US | disclosed |
| EP-1317419-A1 | CYANOPHENOXY CARBOXYLIC ACID COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002020466-A1 | CYANOPHENOXY CARBOXYLIC ACID COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | RXRA 2157/4885RXRB 2226/4885RXRG 2148/4885 |
| US-20060264356-A1 | CYANOPHENOXY CARBOXYLIC ACID COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | CPS1, PCCA, OTC | RXRA 1187/4885RXRB 1225/4885RXRG 884/4885 |
| US-20030199427-A1 | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents | CPS1, PCCA, OTC | RXRA 1187/4885RXRB 1225/4885RXRG 884/4885 |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | RXRA 1871/4885RXRB 1860/4885RXRG 1821/4885 |
| US-20100311748-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | SHH, GLI1, HRH4 | RXRA 96/4885RXRB 118/4885RXRG 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.